Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Covington
Daiichi Sankyo
Colorcon
Cipla
Boehringer Ingelheim
Harvard Business School
Deloitte
Federal Trade Commission

Generated: May 21, 2018

DrugPatentWatch Database Preview

RAVICTI Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Ravicti, and when can generic versions of Ravicti launch?

Ravicti is a drug marketed by Horizon Theraps Inc and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has ninety patent family members in twenty-nine countries.

The generic ingredient in RAVICTI is glycerol phenylbutyrate. There are fifty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the glycerol phenylbutyrate profile page.
Drug patent expirations by year for RAVICTI
Medical Subject Heading (MeSH) Categories for RAVICTI
Synonyms for RAVICTI
611168-24-2
AKOS030238862
Benzenebutanoic acid, 1,1',1''-(1,2,3-propanetriyl) ester
BENZENEBUTANOIC ACID, 1,2,3-PROPANETRIYL ESTER
CHEBI:134745
CHEMBL2105745
D0E0BD
D10127
DB08909
DTXSID40210005
GLYCEROL PHENYLBUTYRATE
Glycerol phenylbutyrate (USAN)
Glycerol phenylbutyrate [USAN]
Glycerolphenylbutyrate
Glyceryl tri-(4-phenylbutyrate)
Glyceryl Tri-4-Phenylbutyrate
GT4P
HPN-100
OR295353
Propane-1,2,3-triyl tris(4-phenylbutanoate)
Ravicti (TN)
SCHEMBL10102804
UNII-ZH6F1VCV7B
ZH6F1VCV7B

US Patents and Regulatory Information for RAVICTI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon Theraps Inc RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Horizon Theraps Inc RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Horizon Theraps Inc RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Horizon Theraps Inc RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for RAVICTI
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Oral Liquid 1.1 g/mL ➤ Subscribe 2013-11-19

Non-Orange Book US Patents for RAVICTI

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,060,510 Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in the treatment of various disorders ➤ Try a Free Trial
6,083,984 Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in the treatment of various disorders ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for RAVICTI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0854 Netherlands ➤ Try a Free Trial PRODUCT NAME: GLYCEROLFENYLBUTYRAAT; REGISTRATION NO/DATE: EU/1/15/1062 20151201
2016041 Lithuania ➤ Try a Free Trial PRODUCT NAME: GLICEROLIO FENILBUTIRATAS; REGISTRATION NO/DATE: EU/1/15/1062 20151127
2016000107 Germany ➤ Try a Free Trial PRODUCT NAME: GLYCEROLPHENYLBUTYRAT; REGISTRATION NO/DATE: EU/1/15/1062 20151127
90060-7 Sweden ➤ Try a Free Trial PRODUCT NAME: GLYCEROL PHENYLBUTYRATE; REG. NO/DATE: EU/1/15/1062 20151201
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
AstraZeneca
Healthtrust
McKinsey
QuintilesIMS
Cerilliant
Farmers Insurance
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.